Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors

Cancer

Volumn 97, Issue 6, 2003, Pages 1541-1550

  Elting, Linda S ^a   Cantor, Scott B ^a   Martin, Charles G ^a   Hamblin, Lois ^a   Kurtin, Danna ^a   Rivera, Edgardo ^a   Vadhan Raj, Saroj ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Complications of chemotherapy; Cost of care; Cost of illness; Incremental costs; Platelet transfusions; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; CEPHALOSPORIN DERIVATIVE; CISPLATIN; DACARBAZINE; DIURETIC AGENT; HEPARIN; HISTAMINE AGONIST; LOMUSTINE; MITOMYCIN C; PENICILLIN DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 11; THROMBOPOIETIN;

ARTICLE; BLEEDING; BONE MARROW METASTASIS; CANCER CHEMOTHERAPY; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECCHYMOSIS; EPISTAXIS; FEMALE; GINGIVA BLEEDING; HEALTH CARE COST; HEMATURIA; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NONHODGKIN LYMPHOMA; PETECHIA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VAGINA BLEEDING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0037443674     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11195     Document Type: Article

References (42)

1. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905-909.
2. Belt RJ, Leite C, Haas CD, et al. Incidence of hemorrhagic complications in patients with cancer. JAMA. 1978;239:2571-2574.
3. Dutcher JP, Schiffer CA, Aisner M, et al. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer. 1984;53:557-562.
4. Goldberg GL, Gibbon DG, Smith HO, et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol. 1994;12:2317-2320.
5. Fanning J, Hilgers RD, Murray KP, et al. Conservative management of chemotherapy-induced thrombocytopenia in women with gynecologic cancers. Gynecol Oncol. 1995;59:191-193.
6. Beutler E. An iconoclastic view of conventional wisdom in hematology. Arch Intern Med. 1979;139:221-223.
7. Baer MR, Bloomfield CD. Controversies in transfusion medicine - Prophylactic platelet transfusion therapy: pro. Transfusion. 1992;32:377-380.
8. Schiffer CA. Prophylactic platelet transfusion [editorial]. Transfusion. 1992;32:295-298.
9. Beutler E. Platelet transfusions: the 20,000/μL trigger. Blood. 1993;81:1411-1413.
10. Pisciotto PT, Benson K, Hume AB, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion. 1995;35:498-502.
11. Norfolk DR, Ancliffe PJ, Contreras M, et al. Concensus conference on platelet transfusion, Royal College of Physicians of Edinburgh. B J Haemat. 1998;101:609-617.
12. Heckman K, Weiner G, Davis C, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/ml versus 20,000/ml. J Clin Oncol. 1997;15:1143-1149.
13. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870-1875.
14. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 < 109/L trigger for prophylactic platelet transfusions compared with 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601-3606.
15. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519-1538.
16. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol. 2000;37(Suppl 4):3-10.
17. Rinder H, Arbini A, Snyder E. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol. 1999;6:437-441.
18. Tepler I, Elias L, Smith II JW, et al. A randomized placebo-controlled trial of recombinant human interteukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607-3614.
19. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997;15:3368-3377.
20. Basser R. Clinical use of thrombopoietic growth factors. In: American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology, 1999: 266-274.
21. Kaushansky K. Drug therapy: thrombopoietin. N Engl J Med. 1998;339:746-754.
22. Elting LS. Integrating prophylactic measures into practice guidelines for platelet growth factors. Oncology. 1999;13:587-589.
23. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19:1137-1146.
24. Malone D, Sullivan S, Black D, et al. The cost of treating chemotherapy-induced thrombocytopenia. Proceedings of ASCO [abstract]. J Clin Oncol. 1995;14:305.
25. Calhoun E, Chang C-H, Welshman E, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001;6:441-445.
26. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative trial of nitrogen mustard and trimethylene thiophosphoramide. J Chron Dis. 1960;11:7-33.
27. Lill M, Snider C, Calhoun L, et al. Epidemiology and cost analysis of platelet transfusions at a tertiary care medical center. Blood Cell and Bone Marrow Transplantation Symposium, Keystone CO, January 1996 [abstract].
28. Hartmann O, Corroller A, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs: a randomized, controlled trial. Ann Intern Med. 1997;126:600-607.
29. Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;91:3509-3517.
30. Jefferies L, Sachais B, Young D. Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion. 2001;41:522-529.
31. Meehan K, Matias C, Rathore S, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hemat. 2000;64:251-256.
32. McCullough J, Steeper T, Connelly D, et al. Platelet utilization in a university hospital. J Am Med Assoc. 1988;259:2414-2418.
33. Zimmerman R, Buscher M, Linhardt C, et al. A survey of blood component use in a German university hospital. Transfusion. 1997;37:1075-1083.
34. Snider C, Erder H, LaBrecque J, et al. What are the true costs of platelet transfusions? A prospective time motion study of resource utilization associated with platelet transfusions at UCLA Medical Center [abstract]. Blood. 1996;88:333a.
35. Balducci L, Benson K, Lyman G, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion. 1993;33:665-670.
36. Ackernan S, Klumpp T, Guzman G, et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion. 2000;40:1457-1462.
37. Lopez-Plaza I, Weissfeld J, Triulzi D. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion. 1999;39:925-932.
38. Freedman J, Gafni A, Garvey M, et al. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion. 1989;29:201-207.
39. Webb I, Anderson K. Risks, costs, and alternatives to platelet transfusions. Leukemia Lymphoma. 1999;34:71-84.
40. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol. 1997;15:2981-2995.
41. Elting L, Martin C, Cantor S, et al. A clinical prediction rule to guide the use of prophylactic platelet growth factors and platelet transfusions. Cancer. 2002;94:3252-3262.
42. Kuter D, Cebon J, Harker L, et al. Platelet growth factors: potential impact on transfusion medicine. Transfusion. 1999;39:321-332.